Quay Pharma are unique in both the academic standing of our scientists, and our drive to discover the most elegant and effective response, not the first or most obvious, to every challenge of drug delivery and dosage. Our senior commercial and technical team brings together an impressive breadth and depth of experience from academia, the pharmaceutical industry and contract service organisations. Their expertise covers chemistry, analytical chemistry, preclinical and clinical formulation development, pharmaceutical development and quality assurance.
Professor Mike Rubinstein
Chairman & Founder
Mike is the Chairman and founder of Quay Pharma. A chemical engineer and pharmacist with Qualified Person (QP) status, he has over 30 years of experience in solid dosage form design, development and manufacture. Before founding Quay Pharma, he was Professor of Pharmaceutical Technology and Director of the School of Pharmacy and Chemistry at Liverpool John Moores University. He is the author of five books on pharmaceutical technology, owns two patents and has published more than 200 research papers and articles. His experience includes work with AstraZeneca and GlaxoSmithKline in both R&D and production.
Chief Executive Officer
Maireadh is the Chief Executive Officer of Quay. She brings more than 16 years experience of business development in an international marketing environment, dealing with the supply of analytical tools and equipment as well as formulation technologies for the pharmaceutical industries. Maireadh’s previous roles include two years as VP with responsibility for Pharmaceutical Business Development at Teraview and eight years at Colorcon managing their EMEA film coating and excipients business.
Professor John Collett
Chief Scientific Officer
John is Quay Pharma’s Chief Scientific Officer and Professor of Pharmaceutics at the University of Manchester. He has over 30 years of experience in formulation science and is the author of more than 250 research papers. His areas of expertise include the formulation of solubilised and modified release drug delivery systems.
Professor Larry Gifford
Chief Scientific Officer
Professor Larry Gifford has been appointed as a Chief Scientific Officer. Alongside Professor John Collett. Prof. Gifford joins us from Keele University where he was Deputy Head of the School of Pharmacy. Prior to Keele, Prof. Gifford taught at the University of Manchester and during his final seven years at Manchester was Head of School, whilst leading an EPSRC post-graduate M.Sc. in Pharmaceutical analysis.and his main interests lie in solid dosage form technology and tablet compression.
Pharmaceutical Development Officer
Mike is our Pharmaceutical Development Officer. He has 13 years industrial experience in product development and production support roles. Before joining Quay Pharma, his positions included Principal Scientific Officer with SSL International and Development Projects Manager at Galpharm International.
Quality Control Manager
Joe is our Quality Control Manager. He oversees all of our GMP laboratory operations, including the QC release of raw materials, finished products. stability testing and equipment cleaning verification. Joe joined us after seven years experience at GlaxoSmithKline.
Head of Quality
Melanie Ackerley is Quay Pharma’s Head of Quality who has successfully qualified as a QP, earlier this month. After completing 4 years of training and releasing Special products in her previous Head of Quality Role, Melanie will now be releasing for Quay Pharma. With a degree in microbiology, a diploma in Quality Assurance, Melanie has worked for over 10 years in pharmaceutical industries such as steriles, biologics, blow fill seal and solid dose in QA, QC and validation roles.
Head of Business Development
Quay Pharma are delighted to announce that Michael Kruidenier has joined as European Business Development Manager. Most of Michael’s career has been spent in commercial roles. He has over 30 years of Sales and Marketing experience, including 14 years in the pharmaceutical industry with Proctor & Gamble and SCA followed by working for leading contract service organisations PERA and Penn Pharma. Michael will be primarily responsible for all sales and marketing activities for mainland Europe and Israel.